Company Profile

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE867.803.3 (+0.38 % )
PREV CLOSE (Rs.) 864.50
OPEN PRICE (Rs.) 859.10
BID PRICE (QTY) 860.00 (11 )
OFFER PRICE (QTY) 871.00 (9 )
VOLUME 80471
TODAY'S LOW / HIGH (Rs.)853.50 873.80
52 WK LOW / HIGH (Rs.)720.4 986
NSE869.20 4.95 (+0.57 % )
PREV CLOSE(Rs.) 864.25
OPEN PRICE (Rs.) 860.00
BID PRICE (QTY) 869.20 (733 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2087687
TODAY'S LOW / HIGH(Rs.) 853.10 874.90
52 WK LOW / HIGH (Rs.)719.8 986.1

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.58
TTM EPS (Rs.) 28.48
P/E Ratio 30.48
Book Value (Rs.) 363.96
Face Value (Rs.) 2
MCap (Rs. in Mn) 392674.03
Price/Earning (TTM) 23.02
Price/Sales (TTM) 3.72
Price/Book (MRQ) 2.38
PAT Margin (%) 13.33
ROCE (%) 11.72
Incorporation Year : 1983

Management Info :

Manju D Gupta - Chairman Nilesh Deshbandhu Gupta - Managing Director

Registered Office :

Address : Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone : 022 6640 2323

Website : www.lupinworld.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
24Apr04-24-2019$USFDA classifies inspection of Lupin's Pithampur facility as OAI USFDA classifies inspection

The United States Food and Drug Administration (USFDA) has classified the inspection conducted at Lupin's Pithampur (Indore) Unit-2 facility in January 2019 as Official Action Indicated (OAI). The USFDA has stated that this facility may be subject to regulatory or administrative action and that it may withhold approval of any pending applications or supplements in which this facility is listed.

The company does not believe that this classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The company is in the process of sending further updates of its corrective actions to the USFDA and is hopeful of a positive outcome.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The United States Food and Drug Administration (USFDA) has clas..
20Apr04-20-2019$Lupin seeks more time from commerce ministry to complete project in Indore SEZ Lupin seeks more time from c

Lupin has sought more time from the commerce ministry to complete its project, with proposed investment of Rs 205.69 crore, in the Indore Special Economic Zone (SEZ). The company is setting up its pharma unit in Indore SEZ to manufacture pharmaceutical formulations - metered dose inhalers and dry powder inhalers.

The company’s plea for extension of time will be considered by the highest decision making body of SEZs - Board of Approval (BoA) in its meeting on April 22.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin has sought more time from the commerce ministry to comple..
16Apr04-16-2019$Lupin gets USFDA’s approval for Fluoxetine Tablets Lupin gets USFDA’s approva

Lupin has received approval for its Fluoxetine Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company’s (Eli Lilly) Prozac Tablets, 10 mg and 20 mg.

The company’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic version of Eli Lilly’s Prozac Tablets, 10 mg and 20 mg. Fluoxetine Tablets, 10 mg and 20 mg, (RLD: Prozac) had annual sales of approximately $68.2 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin has received approval for its Fluoxetine Tablets USP, 10..
16Apr04-16-2019$Lupin gains on getting USFDA’s approval for Fluoxetine Tablets Lupin gains on getting USFDA

Lupin is currently trading at Rs. 836.40, up by 6.20 points or 0.75% from its previous closing of Rs. 830.20 on the BSE.

The scrip opened at Rs. 831.05 and has touched a high and low of Rs. 843.95 and Rs. 827.10 respectively. So far 61199 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 720.40 on 28-Mar-2019.

Last one week high and low of the scrip stood at Rs. 843.95 and Rs. 799.40 respectively. The current market cap of the company is Rs. 37973.27 crore.

The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.

Lupin has received approval for its Fluoxetine Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company’s (Eli Lilly) Prozac Tablets, 10 mg and 20 mg.

The company’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic version of Eli Lilly’s Prozac Tablets, 10 mg and 20 mg. Fluoxetine Tablets, 10 mg and 20 mg, (RLD: Prozac) had annual sales of approximately $68.2 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 836.40, up by 6.20 points or..
12Apr04-12-2019$Lupin launches Testosterone Gel Lupin launches Testosterone

Lupin has launched Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), having received an approval from the United States Food and Drug Administration (USFDA).

The company’s Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie Inc's AndroGel, 1.62%. Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), (RLD: AndroGel) had an annual sales of approximately $893 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin has launched Testosterone Gel, 1.62% (20.25 mg/1.25 g pum..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit1418.213446.6
Gross Profit 3590.5 17939.3
Operating Profit 8195.622169.8
Net Sales 30928100881.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr. Reddys Lab (BSE)
 2924.15 (2.41%)
M.Cap ( in Cr)
48560.17
Jenburkt Pharma (BSE)
 496.40 (2.60%)
M.Cap ( in Cr)
227.82
Aurobindo Pharma (BSE)
 795.60 (1.41%)
M.Cap ( in Cr)
46615.45
Astrazeneca Pharma I (BSE)
 2262.85 (0.46%)
M.Cap ( in Cr)
5657.13
Everest Organics (BSE)
 204.45 (5.01%)
M.Cap ( in Cr)
163.56
Shareholding Pattern More
MUTUAL FUNDS/UTI 6.41 %
FI/BANKS/INSURANCE 5.39 %
PROMOTERS 46.97 %
NON-INSTITUTION 14.96 %
GOVERNMENT 0.28 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested